focus -WSS

focus

author：hotspot 2025-09-28 02:28:52 - browse：382

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Dario to buy mental health app maker Twill in cash and stock deal

WSS

Patient advocates debate FDA's accelerated approval process

New documents shed light on MD Anderson Cancer Institute feud

New documents shed light on MD Anderson Cancer Institute feud

New documents shed light on MD Anderson Cancer Institute feud

Alabama hospital puts IVF treatments on hold

Why the world’s most expensive drug might be worth the price

leisure time

focus

focus

What does generative AI mean for health care? We asked experts

Food as medicine: Medically tailored meals may get standardized

Medical records are filled with copy

6 phony surgeries that take placebo to the extreme

Activists slam private health insurers over coverage restrictions

The Harvard botanist who searched for psychedelics in the Amazon

Hollywood unions extend contract negotiations for actors

Eliminate the waiting period for sterilization covered by Medicaid

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

hotspot

Dario to buy mental health app maker Twill in cash and stock deal

6 phony surgeries that take placebo to the extreme

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

A solution to the after

New documents shed light on MD Anderson Cancer Institute feud

Washington mulls new rules to avert another Change Healthcare

entertainment

leisure time

hotspot

focus